Member Info for ROCKZ

Y-Alam, I appreciate some of your posts but there’s no need to email the company at this point.
We all expected a bit of a drop after demerger, it’s the stock market, drops happen and nothing to worry about. We have seen how swiftly this SP can move.
People need to let the CEO breathe and let him get on with running the company.
7 weeks to hold until Brazil results, main market listing in the meantime. Those who have got their Accustem shares have had a result. That’s all people need to know for now.

Like Oz says, some people would have had the game plan to take their Accustem shares and dump TILS today come rain or shine.
Bit of an artificial drop in that respect. This could move fast when it moves up again.

I think the US will like the Covid RNS and hopefully pull us up for a change this afternoon.
Expecting decent volume later on, could be an interesting afternoon.

Well constructed RNS, hopefully the market will like it.
All the best if you sell, I’ll be holding. Don’t want to risk getting locked out here for the sake of holding for weeks.

Obviously not pleased to see another lockdown but I think we could see the smart money moving into pharma shares like TILS, SNG, VAL and ODX over the next couple of weeks..

Strictlyinc, ‘ Think it might just be SNG last one standing!’
Or maybe Tiziana will be the last one standing?
I’ve looked at SNG as it’s a company located near to where I live. I’ve preferred the TILS option though and I like the fact that if the Brazil Covid trials don’t produce there is still the fallback of Crohns and MS for Foralumab. Then there’s also Milciclib within the pipeline so plenty of cover and potential here.

Yes Adsman, still on track as you describe. Looking to launch in Italy in April followed by UK/Europe then US/Canada.
Website is being constructed as posted by Daveycafe yesterday. It’s only a page read at the moment but encouraging to see and re-emphasis how much superior StemprintER and SPARE is to OncotypeDX. 40-50 per cent.
It’s been an interesting week but happy to be a holder of Accustem now and excited for the future as a LTH.

I believe the $280 million valuation is conservative, mainly due to the fact there are no tangible sales.
As soon as this product starts to sell in Italy, then the UK and Europe the potential of Accustem is going to be realised and this will be reflected in the SP.
In comparison to the main competitor OncotypeDX which was valued at $2.8 billion, Accustem has been proved to be 40 per cent more effective.
For the patient shareholder, Accustem alone could be a $3 billion company within 3-4 years.

Accustem valuation is 280 million dollars. This is the most accurate valuation to date by H.C Wainwright.

Y-Alam, Foralumab was described as the ‘jewel in the crown’, not Milciclib.
That was before Foralumab was considered as a potential Covid treatment so it’s stock has risen some more.

The CEO stated that Accustem will operate as a separate entity to Tiziana and will be a stand alone company. Once demerged, there will be no financial benefit for Tiziana.
The crucial point being is that GC will be the majority shareholder so you can bet your bottom dollar that Accustem will be successful.

Another £1000 added, still chipping away and building as much as possible here. Still expecting a positive squeeze on the SP. Go again next week.

Accustem/StemprintER/Spare will stay under the control of the current team for the foreseeable future, KS was convincing about that last night.

Busy, I am fine with Accustem timeframe as well. Good to hear how confident he was of the team in place achieving commercialisation and he’s also put to bed the belief that a buyer is waiting in the background for StemprintER.
It will grow organically and could be a beast!

No interest from big pharma at this stage in Accustem. Validation will take 4-6 months in Italy and UK.
A while longer before commercialisation is achieved.

Accustem demerger is going ahead and KS is keen for the company to build and not be sold off cheaply.

*US/Canada (let’s not undersell the potential, imagine the cash flow from Canada alone).

The webinar was when Gabrielle mentioned launching StemprintER in Italy first followed by the UK/Europe secondly then US after that.
From memory, I haven’t seen GC or KS mention this on any videos yet.

Agree with a few others here, happy with the gradual daily rises. That way I don’t expect the volatility to be as active post merger. I think I’ll be wrong though for the record and expect a mad day at some point soon.
Exciting times ahead, the jewel in the crown is yet to shine.

*enormous